Evolution of the Average Target: DSM-Firmenich

Evolution of the Target Price: DSM-Firmenich

Changes in Analyst Recommendations: DSM-Firmenich

948286e91fb9c31e.r2fBBYrIbOb-bTBqau_RhwTQczgdgvuB4mbDPqF8Jx8.y1WCc9uGPLmyIQc_DaqT_mmGJHFwup7okw33SMYbUHvhMPJA_YVVoccAeQ~904ed45378b1d67d700c33eb1f58aeb2
06-19 AlphaValue/Baader Europe Downgrades DSM-Firmenich to Reduce, Lifts PT MT
06-09 AlphaValue/Baader Europe Upgrades DSM-Firmenich to Add, Lifts PT MT
06-08 Goldman Sachs Downgrades DSM-Firmenich to Sell, Cuts PT MT
05-22 AlphaValue/Baader Europe Downgrades DSM-Firmenich to Reduce, Lifts PT MT
05-22 Swiss stocks - Factors to watch on May 22 RE
05-06 DSM-Firmenich: Volumes deliver, margin to follow Alphavalue
04-28 KBC Securities weighs in on DSM-Firmenich divestment Zonebourse
03-18 KBC Securities Still Positive on DSM-Firmenich Zonebourse
03-17 Sulfur and methanol prices soar on Middle East conflict Alphavalue
03-13 DSM-Firmenich ready to step up the pace and hit its mid-term targets Zonebourse
03-12 DSM-Firmenich: The story moves from restructuring to delivery Alphavalue
03-11 Kempen Downgrades DSM-Firmenich to Neutral, Cuts PT MT
03-04 Middle East tensions intensify pessimism in chemicals Alphavalue
02-26 AlphaValue/Baader Europe Adjusts Rating, Estimates for DSM-Firmenich on Sale of Animal Nutrition, Health Unit MT
02-25 DSM-Firmenich: ANH Divestment at a Discount May Unlock Growth Potential Alphavalue
02-13 Kepler Cheuvreux Downgrades DSM-Firmenich to Hold, Cuts PT MT
02-12 DSM-Firmenich: Profitability disappoints in FY25 Alphavalue
02-09 DSM-FIRMENICH : Jefferies reaffirms its Buy rating ZD
12-30 Berenberg Reduces DSM-Firmenich PT, Keeps Buy Rating MT
12-30 Berenberg Expects DSM-Firmenich to Retain Minority Stake in Vitamins Business Amid 'Protracted' Deal Talks MT
11-13 Barclays Downgrades DSM-Firmenich to Equalweight, Cuts PT MT
11-11 Goldman Sachs Downgrades DSM-Firmenich to Neutral, Cuts PT MT
30/10/25 DSM-Firmenich: From energy to fatigue: DSM-Firmenich's soft Q3 Alphavalue
22/10/25 AlphaValue/Baader Europe Revises DSM-Firmenich's Price Target Amid 'More Conservative' Outlook MT
20/10/25 DSM-Firmenich: Adopting a more conservative outlook in updated forecast assumptions Alphavalue

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-3.76%
+3.11%
+27.96%
+7.29%
+1.45%
+44.61%
+9.43%
+23.57%
+36.12%
Average +16.64%
Weighted average by Cap. +8.64%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
86.26EUR
Average target price
83.02EUR
Spread / Average Target
-3.76%
High Price Target
103.00EUR
Spread / Highest target
+19.41%
Low Price Target
60.00EUR
Spread / Lowest Target
-30.44%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

AlphaValue/Baader Europe
Goldman Sachs
alphavalue Théodore Duval-Segard
Kempen
Kepler Cheuvreux
JEFFERIES Chris Counihan
Berenberg Bank
Barclays
Deutsche Bank Research
BNP Paribas
Stifel Nicolaus
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
86.26EUR
Average target price
83.02EUR
Spread / Average Target
-3.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DSFIR Stock
  4. Consensus DSM-Firmenich